Stock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement

Stock Track

01/08

MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.

The company announced a positive outcome from a Type B meeting with the U.S. FDA, confirming it can establish SEE without additional trials. Additionally, MoonLake revealed plans to host an Investor Day on February 23, 2026, to discuss FDA feedback, share new clinical data, and outline its 2026 catalyst calendar.

Further boosting investor confidence, MoonLake disclosed plans to submit a Biologics License Application (BLA) for SLK in HS in the second half of 2026, signaling progress in its pipeline.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1116502352"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1116502352\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1116502352?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 21:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116502352","market":"sg","top_or_hot":-1,"title":"Stock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement","media":"Stock Track","content":"<p>MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.</p><p>The company announced a positive outcome from a Type B meeting with the U.S. FDA, confirming it can establish SEE without additional trials. Additionally, MoonLake revealed plans to host an Investor Day on February 23, 2026, to discuss FDA feedback, share new clinical data, and outline its 2026 catalyst calendar.</p><p>Further boosting investor confidence, MoonLake disclosed plans to submit a Biologics License Application (BLA) for SLK in HS in the second half of 2026, signaling progress in its pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MoonLake Immunotherapeutics Soars 43.58% in Pre-Market on FDA Feedback and Investor Day Announcement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-08 21:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.</p><p>The company announced a positive outcome from a Type B meeting with the U.S. FDA, confirming it can establish SEE without additional trials. Additionally, MoonLake revealed plans to host an Investor Day on February 23, 2026, to discuss FDA feedback, share new clinical data, and outline its 2026 catalyst calendar.</p><p>Further boosting investor confidence, MoonLake disclosed plans to submit a Biologics License Application (BLA) for SLK in HS in the second half of 2026, signaling progress in its pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLTX","symbol_name":"MoonLake Immunotherapeutics","start_time":0,"source_url":"","article_id":"1116502352","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116502352","pubTimestamp":1767878080,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.The company announced a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MLTX":"MoonLake Immunotherapeutics"},"translate_title":"个股追踪|FDA反馈及投资者日公告MoonLake Immunotherapeutics盘前大涨43.58%","themeId":"33791b051befbfd8525af904615f530c","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":1},"content_text":"MoonLake Immunotherapeutics (MLTX) surged 43.58% in pre-market trading on Thursday, driven by positive developments including FDA feedback and plans for an Investor Day.The company announced a positive outcome from a Type B meeting with the U.S. FDA, confirming it can establish SEE without additional trials. Additionally, MoonLake revealed plans to host an Investor Day on February 23, 2026, to discuss FDA feedback, share new clinical data, and outline its 2026 catalyst calendar.Further boosting investor confidence, MoonLake disclosed plans to submit a Biologics License Application (BLA) for SLK in HS in the second half of 2026, signaling progress in its pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}